Rare diseases
Investigational molecules
Locations
Kloosterstraat 9, 5349 AB, The Netherlands
The sponsor demonstrates concentrated expertise in B-cell malignancies, with particular emphasis on chronic lymphocytic leukemia and mantle cell lymphoma. Research initiatives explore novel therapeutic approaches for patients with relapsed or refractory disease, including those who have experienced treatment failure with prior therapies. The investigational portfolio addresses both treatment-naïve populations and patients with progressive disease following Bruton's tyrosine kinase inhibitor therapy.
Clinical programs evaluate combination regimens incorporating targeted kinase inhibitors with established immunotherapeutic agents, aiming to enhance treatment efficacy while managing safety profiles in diverse patient populations.
Acerta Pharma B.V. runs clinical trials in conditions such as Chronic lymphocytic leukaemia, Waldenstrom's macroglobulinaemia recurrent, Waldenstrom's macroglobulinaemia refractory, Prolymphocytic leukaemia, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Belgium
Austria
France
Italy
Croatia
PolandAustriaFranceBelgiumItalyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
